Trial Profile
Concomitant Tarceva and Irradiation in Patients in Local-Regionally Advanced Non-Small Cell Lung Cancer. A Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2020
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TARLAL
- 19 May 2016 Status changed from recruiting to completed.
- 14 Nov 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 24 Apr 2009 New trial record